Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ONCOLOGY / CLINICAL RESEARCH
Relationship between clinical characteristics and serum tumor markers in connective tissue disease with interstitial lung disease as the initial manifestation
1
Shanxi Bethune Hospital, China
These authors had equal contribution to this work
Submission date: 2024-05-27
Final revision date: 2025-04-19
Acceptance date: 2025-04-20
Online publication date: 2025-08-19
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Interstitial lung disease (ILD) is a common complication of connective tissue disease (CTD), which seriously affects the prognosis of patients. The abnormal expression of tumor markers in non-neoplastic diseases may be related to the occurrence and development of CTD-ILD. This study aimed to explore the detailed clinical characteristics of CTD-ILD, and to analyze their association with serum tumor markers.
Material and methods:
The clinical data of 128 patients with CTD-ILD were retrospectively analyzed. Seventy-nine ILD patients without CTD were enrolled as the non-combined group. Clinical data included imaging manifestations, laboratory indices and tumor markers such as carbohydrate antigen (CA) 125, CA153, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and squamous cell carcinoma (SCC) antigen were collected. ROC curve analysis was used to assess the clinical value of these markers.
Results:
The proportion of clinical manifestations such as arthralgia, rash, Raynaud’s phenomenon, dry mouth and dry eyes in the combined group was higher than in the non-combined group (p < 0.05). The serum albumin and total protein levels in the combined group were lower than in the non-combined group (p < 0.001). The levels of CA125, CA153, CEA, SCC, and NSE in the combined group were higher than in the non-combined group (p < 0.001). The AUC of combined detection of each index was 0.917, with a sensitivity of 97.47% and a specificity of 76.56%.
Conclusions:
The main clinical manifestations for CTD-ILD patients were arthralgia, rash, Raynaud’s phenomenon, and dry mouth and eyes. The combined detection of tumor markers had high evaluation value.
Interstitial lung disease (ILD) is a common complication of connective tissue disease (CTD), which seriously affects the prognosis of patients. The abnormal expression of tumor markers in non-neoplastic diseases may be related to the occurrence and development of CTD-ILD. This study aimed to explore the detailed clinical characteristics of CTD-ILD, and to analyze their association with serum tumor markers.
Material and methods:
The clinical data of 128 patients with CTD-ILD were retrospectively analyzed. Seventy-nine ILD patients without CTD were enrolled as the non-combined group. Clinical data included imaging manifestations, laboratory indices and tumor markers such as carbohydrate antigen (CA) 125, CA153, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and squamous cell carcinoma (SCC) antigen were collected. ROC curve analysis was used to assess the clinical value of these markers.
Results:
The proportion of clinical manifestations such as arthralgia, rash, Raynaud’s phenomenon, dry mouth and dry eyes in the combined group was higher than in the non-combined group (p < 0.05). The serum albumin and total protein levels in the combined group were lower than in the non-combined group (p < 0.001). The levels of CA125, CA153, CEA, SCC, and NSE in the combined group were higher than in the non-combined group (p < 0.001). The AUC of combined detection of each index was 0.917, with a sensitivity of 97.47% and a specificity of 76.56%.
Conclusions:
The main clinical manifestations for CTD-ILD patients were arthralgia, rash, Raynaud’s phenomenon, and dry mouth and eyes. The combined detection of tumor markers had high evaluation value.
REFERENCES (29)
1.
Kondeti RD, Venkatesh K, Murthy D, Kameti S, Devi KS, Chandrika KV. A study of clinical manifestations and their association with antinuclear antibodies in various autoimmune connective tissue disorders. Indian J Dermatol 2023; 68: 486.
2.
Kuryliszyn-Moskal A, Hryniewicz A, Bagiński N, Moskal-Jasińska D, Dzięcioł-Anikiej Z, Dzięcioł J. Foot static disturbances and clinical features in overweight patients with rheumatoid arthritis. Arch Med Sci 2020; 19: 1774-80.
3.
Hernández Muñiz S, Olivera Serrano MJ, Jiménez Heffernan JA, Valenzuela C, Caballero Sánchez-Robles P. Interstitial disease associated with connective tissue disease and vasculitis. Radiologia 2022; 64 (Suppl): 250-64.
4.
Vacchi C, Sebastiani M, Cassone G, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. a narrative review. J Clin Med 2020; 9: 407.
5.
Cerro C.G, Parimon T. Understanding interstitial lung diseases associated with connective tissue disease (CTD-ILD): genetics, cellular pathophysiology, and biologic drivers. Int J Mol Sci 2023; 24: 2405.
6.
Aparicio IJ, Lee JS. Connective tissue disease-associated interstitial lung diseases: unresolved issues. Semin Respir Crit Care Med 2016; 37: 468-76.
7.
Mlika M, Braham E, Mezni F. Interstitial lung disease: elementary lesions and diagnosis. Semin Diagn Pathol 2018; 35: 288-96.
8.
Pugashetti JV, Khanna D, Kazerooni EA, Oldham J. Clinically relevant biomarkers in connective tissue disease-associated interstitial lung disease. Immunol Allergy Clin North Am 2023; 43: 411-33.
9.
Lim CH, Tseng CW, Lin CT, et al. The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: a retrospective study. SAGE Open Med 2018; 6: 1-8.
10.
Gao K, Lian W, Zhao R, Xiong J. Characteristics of patients with stage III and IV ovarian endometriomas and trends in postoperative anti-Mullerian hormone changes. Arch Med Sci 2023; 19: 800-4.
11.
Lian M, Zhang C, Zhang D, et al. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer. J Clin Lab Anal 2019; 33: e22875.
12.
Hata A, Nakajima T, Matsusaka K, et al. Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis. Int J Cancer 2021; 148: 3008-18.
13.
Yan P, Han Y, Tong A, Liu J, Wang X, Liu C. Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer. Biosci Rep 2021; 41: BSR20210866.
14.
Gonzalez-Exposito R, Semiannikova M, Griffiths B, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer 2019; 7: 101.
15.
Robalo-Cordeiro C, Morais A. Translating idiopathic pulmonary fibrosis guidelines into clinical practice. Pulmonology 2021; 27: 7-13.
16.
Mansournia MA, Collins GS, Nielsen RO, et al. A CHecklist for statistical Assessment of Medical Papers (the CHAMP statement): explanation and elaboration. Br J Sports Med 2021; 55: 1009-17.
17.
Oliveira RP, Ribeiro R, Melo L, Pereira CAC. Connective tissue disease-associated interstitial lung disease. Pulmonology 2022; 28: 113-8.
18.
Joy GM, Arbiv OA, Wong CK, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev 2023; 32: 220210.
19.
Stanel SC, Callum J, Rivera-Ortega P. Genetic and environmental factors in interstitial lung diseases: current and future perspectives on early diagnosis of high-risk cohorts. Front Med 2023; 10: 1232655.
20.
Spagnolo P, Distler O, Ryerson CJ, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis 2021; 80: 143-50.
21.
Watanabe K, Horita N, Hara Y, Kobayashi N, Kaneko T. Clinical features of asthma with connective tissue diseases. Clin Respir J 2023; 17: 303-10.
22.
Luppi F, Sebastiani M, Silva M, et al. Interstitial lung disease in Sjögren’s syndrome: a clinical review. Clin Exp Rheumatol 2020; 38 Suppl 126: 291-300.
23.
Zhu W, Li Y, Zhao J, Wang Y, Li Y, Wang Y. The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking. Ann Med 2022; 54: 541-52.
24.
Wang Y, Sun D, Song Y, Du X, Wu N, Ye Q. Assessment of tumor biomarkers for prognosis in interstitial lung disease associated with connective tissue disease: a prospective study. J Thorac Dis 2024; 16: 7383-96.
25.
Bao Y, Zhang W, Shi D, Bai W, He D, Wang D. Correlation between serum tumor marker levels and connective tissue disease-related interstitial lung disease. Int J Gen Med 2021; 14: 2553-60.
26.
Wei F, Zhang X, Yang S, et al. Evaluation of the clinical value of KL-6 and tumor markers in primary Sjögren’s syndrome complicated with interstitial lung disease. J Clin Med 2023; 12: 4926.
27.
Kwon BS, Kim ES, Lim SY, et al. The significance of elevated tumor markers among patients with interstitial lung diseases. Sci Rep 2022; 12: 16702.
28.
Zheng M, Lou A, Zhang H, Zhu S, Yang M, Lai W. Serum KL-6, CA19-9, CA125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the Chinese population. Rheumatol Ther 2021; 8: 517-27.
29.
Shi L, Han XL, Guo HX, et al. Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial lung disease. Ther Adv Chronic Dis 2020; 11: 2040622320944802.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
